DeCure for Congenital anomalies of kidney and urinary tract syndrome with or without hearing loss, abnormal ears, or developmental delay
DeCure's autonomous Nephrology AI scientist is researching a drug-repurposing hypothesis for congenital anomalies of kidney and urinary tract syndrome with or without hearing loss, abnormal ears, or developmental delay — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCongenital anomalies of kidney and urinary tract syndrome with or without hearing loss, abnormal ears, or developmental delay maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for congenital anomalies of kidney and urinary tract syndrome with or without hearing loss, abnormal ears, or developmental delay is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
PBX homeobox 1 (PBX1) — PBX1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1B72 · 2.35 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
The abstracts provided do not describe any drug treatment or repurposing study for congenital anomalies of the kidney and urinary tract (CAKUT). One abstract states that CAKUT is found in 3–6 per 1,000 newborns, or in 0.5% of all pregnancies, and that it includes renal, bladder, and urethral anomalies. Another notes that CAKUT accounts for about 40–50% of patients under 21 with chronic kidney disease worldwide, and that most cases are diagnosed in utero or in the first months of life. A third abstract describes a clinical case of multicystic dysplasia of the left kidney in a newborn and discusses management by a multidisciplinary team.
No drug, no intervention, no survival or response rate data appear in any of the three abstracts. The 2024 genetic review states that the problem of urinary system anomalies remains relevant despite contributions from genetics, but it does not report any therapeutic trial or outcome. The 2017 study is described as retrospective-prospective and includes newly diagnosed and previously diagnosed patients, but it gives no results.
What is missing is any clinical trial testing a drug for CAKUT, any repurposing hypothesis, any patient stratification strategy, and any funding for such work. The abstracts offer epidemiology and genetics, not treatment evidence.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PRILOZI · 2017 · 6 citations · open access
Congenital Anomalies of the Kidney and Urinary Tract (CAKUT)
AbstractCongenital anomalies of the kidneys and urinary tract (CAKUT) are found in 3-6 out of 1.000 of the newborns, or according to some statistics they are represented in 0.5% of all pregnancies. Congenital abnormalities of the kidneys and urinary tract present a family of diseases of various anatomic spectrum, including renal anomalies, and anomalies of the bladder and urethra. The study was retrospective-prospective which means that it included newly diagnosed patients suffering from CAKUT, as well as those patients with already diagnosed and well defined CAKUT on the basis of imaging studies which have been processed according to the protocol for this study.
Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) · 2024 · 0 citations · open access
Genetic aspects of the development of congenital anomalies of the kidney and urinary tract
AbstractCongenital anomalies of the kidney and urinary tract (CAKUT) include a wide range of structural anomalies that develop as a result of impaired morphogenesis of the kidneys and/or urinary tract. CAKUT accounts for about 40–50% of patients under 21 with chronic kidney disease worldwide. Most congenital anomalies of the urinary system are diagnosed in utero or during the first months of a child’s life, which determines further tactics for managing a child, depending on the severity of CAKUT and the degree of decrease in the filtration function of the kidneys. The article provides modern data on the causes of the development of anomalies of the urinary system, provides examples of the development of scientific areas that will be aimed at predicting the occurrence of malformations. In addition, early markers of the disease are considered. Thus, the problem of anomalies of the urinary system remains relevant to the present despite the significant contribution of genetics to understanding the pathogenesis and predicting the development of CAKUT.
Neonatology surgery and perinatal medicine · 2024 · 0 citations · open access
CLINLCAL CASE OF MULTICYSTIC DYSPLASIA OF THE LEFT KIDNEY IN A NEWBORN CHILD – SCIENTIFIC AND APPLIED REALITIES
AbstractThe clinical picture of congenital anomalies of the kidneys and urinary tract can vary from isolated renal anomalies to syndromic phenotypes. The modern components of management of congenital anomalies of the kidneys and urinary tract, described in the article on the example of a clinical case of congenital polycystic dysplasia of the left kidney, will help to deepen the scientific and applied competencies of doctors who are part of a multidisciplinary team of medical process of this congenital developmental anomaly, as well as parents or persons responsible for the child.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
